OptoPath development followed two phases:
Phase 1 (2011-2016): Acquiring, and Developing new cutting-edge equipment that were not commercially available worldwide for in vivo behavioral and neurobiological investigations.
Phase 2 (starting in August 2016): Valorizing these new equipment and behavioral models through different main strategies:
- Conducting collaborative research projects to both academia and pharmaceutical industries for the identification of new therapeutic targets for high impact pathological conditions: Addiction, Obesity, Memory deficits and Anxiety-related disorders
- Marketing the new cutting-edge instruments which have been developed with Imetronic, our industrial partner
- Marketing to pharmalogical companies new and unique services offers (neurobiological, behavioral and neurobiological-behavioral coupled studies) in the context of Drug Abuse, Obesity, Memory deficits and PTSD/Anxiety-related disorders
- Propose innovative and unique Training offers